reason report
recap strong start year end-market continu
bottom line remain op-rat view
compani life scienc tool leader unmatch scale
access multipl grow end market deliv organ
revenu growth vs us street out-
perform across segment end-market remain healthi
analyt technolog deliv anoth averag growth
quarter come y/i organ back strength lc-m
chemic analysi fei electron microscopi also rais full
year revenu ep guid given backdrop pt remain
uniqu time life scienc tool end-market continu
deliv view appropri baromet life scienc
tool lst compani given size access divers end-market
rare end-market academ biopharma asia
deliv strongli consist pharma end-market deliv
organ growth academ end-market grew mid-singl digit
industri high-singl digit diagnost deliv low singl digit
growth quarter uniqu point exact hf-x high
re mass spec strong contributor growth year sinc launch
 like drive market expans share gain vs competitor
specialti diagnost segment see higher incid flu
growth meaning compani level
china momentum continu despit tougher comp china
anoth big contributor deliv high-teen growth even
tough comp emerg market repres
revenu china appear experienc growth across
market includ appli food environment industri
outlook even stronger accord appear recent
tariff nois china dampen enthusiasm
expect continu momentum china asia broadli
compani also held china-u precis medicin confer
particip highlight grow precis medicin effort china
guidanc rais also rais full year guid come
vs prior revenu growth still organ
revenu growth guid remain ep guid grew
 continu expect bp oper
margin expans year estim move
vs
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
compani inform leerink partner llc research
revenu ep exclud charg amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate thermo fisher scientif outperform price target
remain outperform-r given view compani life scienc tool
lst leader unmatch scale reach research lab market combin
number growth product serv key end-market also acquiror view
consolid sizabl portion lst market patheon acquisit close
believ potenti consolid contract develop manufactur
organ industri long term view posit given sheer
scale reput presenc lst market biopharma academ channel
industrial/environment diagnost deliv manag forecast grow
solidifi presenc emerg market asia-pacif china revenu
continu strength biopharma end-market view sign slow
near term inorgan growth continu remain key prioriti next
year capit deploy estim suggest debt/
ebitda leverag longer term said also cogniz amzn penetr lab
suppli channel stronghold merger fisher scientif
share current trade ev/ebitda line large- mid-
cap tool averag ev/ebitda given
continu exposur tailwind biopharma china believ hold
posit lead lab tool suppli provid howev entri lab
suppli busi despit earli stage lend caution expect
trade ev/ebitda multipl higher end lst averag histor
result deriv price target appli multipl ebitda estim
primari risk price target includ
slowdown global budget research could caus downsid risk forecast
tighten budget govern academ fund could result lower revenu
rel estim furthermor restrict global budget could result shift focu
strategi growth could increas oper risk declin government spend
could risk downsid forecast growth nih spend
biopharma declin pose greatest risk tmo revenu declin biopharma fund
could highli impact revenu given third revenu lever biopharma
industri slowdown biopharma fund would result downsid risk estim
valuat biomolecul forecast ramp drug market mid-teen
estim hing prolifer drive use tmo bioprocess
equip mass spectromet instrument reagent character
scale diversif could backfir tmo size diversif
advantag compani consolid space pose signific challeng term
move needl growth perspect given size acquisit
alreadi done includ life pthn transact would ventur estim
deal size least grow north organ make signific move
market although asset might visibl street given limit public
asset larg number privat asset could potenti avail howev
pose risk street might appreci capabl asset enough
move needl
emerg market pose signific risk tmo revenu geopolit risk
emerg market could disrupt oper downsid risk valuat forecast
risk could countri region specif could also impact tmo strategi creat
higher barrier entri exist futur market local product reagent prefer
import oper numer intern market includ india
china eastern europ name
tmo exposur china could also pose concentr risk china repres
tmo revenu macroeconom impact chines market could lead declin
compani revenu regul chines polici could also caus restrict oper
lead lower activ china question remain china relat
detail headwind could emerg polici risk
 synergi may go plan tmo acquisit sizabl may go
plan could result integr risk lower-than-expect synergi integr
requir cultur process adapt synergi model forecast
risk estim remain integr unquantifi aspect target
forecast model margin eros could occur under-perform
increas risk amazon distribut busi like impact revenu
tmo laboratori product servic lp busi custom shown
will consid amazon vendor consum product expir
date beaker pipett expect amazon expertis logist suppli chain
allow amazon offer product competit cost thu impact lp revenu overal
dollar million except per share data
good sold
net incom continu op
sg sale
 sale
oper expens sale
compani report leerink partner estim
